# Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease

> **NCT06175468** · PHASE3 · UNKNOWN · sponsor: **China Medical University Hospital** · enrollment: 170 (estimated)

## Conditions studied

- Influenza Viral Infections
- COVID-19

## Interventions

- **DRUG:** Formosa 1-Breath Free (NRICM101)
- **DRUG:** Placebo control drug

## Key facts

- **NCT ID:** NCT06175468
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-15
- **Primary completion:** 2024-04
- **Final completion:** 2024-08
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175468, "Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06175468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*